Celiac Disease Foundation is pleased to announce the March 30-31, 2015, U.S. Food and Drug Administration (FDA) public workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3). This scientific meeting will address endpoints and outcome measures for clinical trials for products intended to treat adult and/or pediatric celiac disease and inflammatory bowel disease.
Currently, the typical treatment for a patient diagnosed with celiac disease is a strict gluten-free diet for life. Future therapies currently in the pipeline hope to make living with celiac disease less of a burden.
For people with celiac disease, vaccinations tend to work just as effectively as they do for the general population with one notable exception: hepatitis B. Celiac disease testing is recommended for non-responders to the hepatitis B vaccine who are not already diagnosed.
Celiac Disease (CD), a genetic condition affecting 1% of the population, is somewhat unique among autoimmune conditions in that it has an effective treatment in the gluten-free diet. However, the diet can be difficult to follow; a significant proportion of CD patients do not respond to the diet with the expected intestinal healing, typically due […]
The U.S. Preventative Services Task Force (USPSTF) has posted its research plan for the screening of the U.S. population for celiac disease. The research plan is designed to answer seven key questions about screening. These questions are: What is the effectiveness of screening versus not screening for celiac disease in asymptomatic adults, adolescents, or […]
Celiac disease remains one of the most common autoimmune diseases, affecting approximately 1% of the population in the United States. Celiac disease is genetic; having a first degree relative with it means you are about ten times more likely to develop the disease. However, almost one third of the U.S. population has the genetic components […]
On August 5th, 2013, the FDA issued its final ruling on the label “gluten-free” and when it could be applied to packaged foods under the FDA’s purview. The compliance date for this ruling, August 5th, 2014, has come and gone, and two studies have been published that investigated the level of gluten in foods labeled […]
Currently, the primary treatment for celiac disease (CD) is a strict and lifelong gluten-free diet, which can saddle patients with heavy financial and social burdens. On top of this, many patients continue to get exposed to gluten accidentally, preventing their intestines from healing properly. Other forms of treatment, such as Alvine Pharmaceutical’s ALV003, are being […]
In the past, celiac disease (CD) was thought of as a children’s malabsorptive disease, but CD patients can experience many non-gastrointestinal symptoms, and a recent paper from Italy attempted to review how CD can affect the reproductive health of women.
The risk for certain types of malignancy in celiac disease (CD) patients has long been a cause for concern. Other types of cancers, such as breast cancer and lung cancer, may be less common in subjects with CD. Studies in the US and UK have pegged the overall increase in risk for malignancy at about […]